1. Generics Bulletin
  2. >>Products

AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Up To Nine Adalimumab Biosimilars to Launch In Key Year

 
• By Dean Rudge

Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.

Billion_Dollar
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock

Two biosimilar Humira (adalimumab) products that are set to enter the US market upon formation in 2023 will hold controversial interchangeability designations, according to originator AbbVie’s latest modelling assumptions for the world’s best-selling drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products